Evaluating Nuvalent as an investment changed drastically following its definitive buyout by GSK plc at a substantial cash tender price per share. While it previously operated as an independent clinical-stage biopharmaceutical company carrying typical pipeline development risks, its acquisition by a major pharmaceutical enterprise provided public shareholders with a definitive, premium cash realization for their equity holdings.